Search PubMed⌕ Search

Biomedical subjects

A Fuentes

Publications and source records attributed to A Fuentes.

At least 91 records · Page 5Linked to original sources
PubMedDate not supplied

Recertification in cardiopulmonary resuscitation. A comparison of two teaching methods.

In this study, the authors compare knowledge scores, pass/fail rate, time spent, satisfaction, and skill retention between two teaching methods used in cardiopulmonary resuscitation (CPR) recertification. Seventy subjects were assigned randomly to either traditional or computer method of instruction. Knowledge was evaluated by written examination. Psychomotor skills were evaluated either by a Basic Cardiac Life Support certified instructor (control group) or the computer (experimental group) and reevaluated by an instructor at a 6-month interval. There was no significant difference between the groups in knowledge or performance scores. However, significant differences in time spent, learner satisfaction, and pass/fail rate all favored the traditional method of instruction. These findings conflict with the results of prior studies on the use of the computer interactive learning system.

Adult↗
PubMedDate not supplied

Preclinical pharmacology of the natural marine product dolastatin 10 (NSC 376128).

The preclinical pharmacology and pharmacokinetics of the natural marine product dolastatin 10 were investigated. Pharmacokinetics of [3H]dolastatin 10 were determined in CD2F1 mice after intravenous, subcutaneous, and intraperitoneal routes of administration. After intravenous injection (0.24 mg/kg), plasma drug concentration declined rapidly and was cleared from plasma with a half-life of 5.6 hr. After a subcutaneous dose of 0.32 mg/kg, dolastatin 10 concentrations slowly rose to a maximum of 11 ng/ml and then declined with an elimination half-life of 3.7 hr. Most of the radioactivity in plasma was found to be from drug-derived radiolabeled products and not from parent compound. Urinary excretion of dolastatin 10 was < 2% of the administered dose, irrespective of the route of administration. In vitro, dolastatin 10 was stable in mouse plasma for at least 24 hr at 37 degrees C. The drug was also highly protein-bound (> 81%) in human, dog, and mouse plasmas. Dolastatin 10 underwent rapid conversion to more polar products after incubation with whole liver homogenate or the S9 fraction from rate liver. One of these metabolites was identified by mass spectrometry as a dihydroxy derivative of dolastatin 10.

Animals↗